Skip to main content
SLSBio(Specialty Lab Solution Bio) Co., Ltd logo

SLSBio(Specialty Lab Solution Bio) Co., Ltd — Investor Relations & Filings

Ticker · 246250 ISIN · KR7246250005 KO Professional, scientific and technical activities
Filings indexed 260 across all filing types
Latest filing 2026-03-27 Board/Management Inform…
Country KR South Korea
Listing KO 246250

About SLSBio(Specialty Lab Solution Bio) Co., Ltd

http://www.slabs.co.kr/

SLSBio (Specialty Lab Solution Bio) Co., Ltd. is a company specializing in laboratory solutions and support services for the pharmaceutical and biotechnology sectors. Its primary offerings include pharmaceutical quality control testing, clinical trial sample analysis, bioequivalence studies, drug stability testing, and new drug development support. In addition to its service portfolio, the company develops and manufactures diagnostic technologies, reagents, and other biological agents, supporting various stages of the drug development and commercialization lifecycle.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a regulatory notice (신고) filed with the Financial Services Commission/Korea Exchange regarding the appointment, dismissal, or mid-term resignation of outside directors (사외이사). It details changes in board composition (number of outside directors before and after, individual appointment details). This matches the definition of Board/Management Information (MANG).
2026-03-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is the official results of an Annual General Meeting (정기주주총회결과) held on 2026-03-27, detailing resolutions passed (approval of financial statements, director and auditor appointments, articles of association changes, etc.) and the voting percentages for each agenda item. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (Code: DVA)", which covers official results from shareholder votes at any general meeting.
2026-03-27 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'SLS Bio' (주식회사 에스엘에스바이오). It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It covers the fiscal period from January 1, 2025, to December 31, 2025. While it contains financial data, it is a formal audit report rather than a general annual report (10-K) or a simple earnings release. Given the specific category 'Audit Report / Information' (AR), this is the most accurate classification. FY 2025
2026-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data, and auditor information for the fiscal year ending 2025-12-31. While it contains financial data, it is a standard regulatory disclosure announcement regarding the filing of the audit report rather than the full annual report (10-K) itself. According to the 'Menu vs Meal' rule, this is a report publication announcement. FY 2025
2026-03-12 Korean
기타시장안내 (상장적격성 실질심사 사유추가)
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement from a stock exchange regarding the addition of a 'listing eligibility review' (상장적격성 실질심사) for the company SLS Bio. It is a formal regulatory notice concerning market status and compliance, which does not fit into specific categories like financial reports or M&A, making it a standard regulatory filing.
2026-03-12 Korean
반기또는분기매출액미달사실발생
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure regarding a 'failure to meet semi-annual or quarterly revenue thresholds' (specifically below 700 million KRW). It is a formal regulatory filing required by the exchange to notify investors of a specific financial event or compliance status. Since it does not constitute a full financial report, a transcript, or a management presentation, but rather a specific regulatory notification of a financial condition, it falls under the RNS (Regulatory Filings) category. H1 2025
2026-03-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.